Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,105 across all filing types
Latest filing 2017-03-02 Director's Dealing
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
Director's Dealing 2017
Director's Dealing
2017-03-02 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to the offering of debt securities (notes) by Johnson & Johnson. It includes detailed information about the terms of the notes, registration fees, underwriting details, risk factors, use of proceeds, and legal matters. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act of 1933. This type of document is a capital/financing update as it relates to the issuance of new debt securities and fundraising activities. It is not an annual report, earnings release, or any other type of report. The length of the document (15,000 characters) and the detailed content confirm it is the actual prospectus supplement, not just an announcement. Therefore, the correct classification is Capital/Financing Update (CAP).
2017-03-01 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a Pricing Term Sheet for a bond issuance by Johnson & Johnson, filed pursuant to Rule 433. It details terms of a 3.750% Senior Unsecured Notes due 2047, including size, maturity, coupon, pricing, and underwriting details. This type of document is related to capital raising activities and financing terms, not a full financial report or earnings release. It is not an announcement of a report publication but a primary document describing a financing offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short but contains substantive financing details, not just a notice or announcement. Confidence is high due to clear identification of bond issuance terms and regulatory filing context.
2017-03-01 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a Pricing Term Sheet for a bond issuance by Johnson & Johnson, filed pursuant to Rule 433. It details the terms of a 3.625% Senior Unsecured Notes due 2037, including size, maturity, coupon, pricing, and underwriting details. This type of document is related to the company's capital raising activities and financing terms. It is not a full financial report, earnings release, or regulatory filing about financial results. It is not an announcement of a report publication but a direct update on financing terms. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused solely on financing terms, confirming this classification with high confidence.
2017-03-01 English
FWP
Capital/Financing Update Classification · 100% confidence The document is a Pricing Term Sheet for a debt offering by Johnson & Johnson, detailing terms of 2.950% Senior Unsecured Notes due 2027. It is filed pursuant to Rule 433, which relates to free writing prospectuses used in securities offerings. The content focuses on the terms of a new debt issuance, including coupon, maturity, pricing, and underwriting details. This matches the definition of a Capital/Financing Update, which covers company fundraising and financing activities. The document is short (2470 characters) and is not an announcement of a report publication or a certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-03-01 English
FWP
Capital/Financing Update Classification · 100% confidence The document is a Pricing Term Sheet for a bond issuance by Johnson & Johnson, detailing terms such as coupon rate, maturity date, size, underwriting discount, and ratings. It is filed pursuant to Rule 433, which relates to free writing prospectuses in securities offerings. The content focuses on the terms of a debt issuance and financing activity, not on financial results, management changes, or regulatory filings. The document length is short (2472 characters) and it is clearly a capital markets communication about a financing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-03-01 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.